Protia Inc. (KOSDAQ:303360)

Market Cap	58.72B +37.3%
Revenue (ttm)	16.25B +43.8%
Net Income	4.74B +83.1%
EPS	312.01 +82.6%
Shares Out	12.88M
PE Ratio	14.61
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	30,039
Average Volume	33,422
Open	4,670.00
Previous Close	4,560.00
Day's Range	4,535.00 - 4,670.00
52-Week Range	2,935.00 - 6,890.00
Beta	0.36
RSI	38.48
Earnings Date	n/a

About Protia

Protia Inc. manufactures and sells in vitro diagnostic medical devices in South Korea. It offers allergy, animal diagnosis, autoimmune, antibiotic susceptibility, POCT, cancer, and related instrument products, as well as protein analysis, LC-MS/MS, characterization analysis, and custom protein services. The company was formerly known as ProteomeTech Inc. and changed its name to Protia Inc. in November 2023. Protia Inc. was founded in 2000 and is headquartered in Seoul, South Korea.

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2000
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 303360

Financial Performance

In 2025, Protia's revenue was 15.12 billion, an increase of 43.80% compared to the previous year's 10.51 billion. Earnings were 4.47 billion, an increase of 83.09%.